Why Ketamine Dosing Is Complex
Ketamine dosing is not a one-size-fits-all calculation. The appropriate dose depends on several interacting factors: the route of administration, the patient's body weight, the condition being treated, individual sensitivity, prior medication history, and the specific treatment protocol the clinician follows.
Unlike many psychiatric medications that are taken daily at a fixed dose, ketamine therapy typically involves intermittent dosing sessions with careful titration. Understanding how your clinician approaches dosing helps you engage more meaningfully in your treatment and set realistic expectations.
Route of Administration: The Biggest Variable
The single most important factor in understanding ketamine dosing is the route of administration. Because bioavailability differs dramatically across routes, the same "amount" of ketamine produces very different effects depending on how it enters the body.
Intravenous (IV) Ketamine
- Typical dose for depression: 0.5 mg/kg infused over 40 minutes
- Bioavailability: 100%
- Setting: Clinical infusion center
- Onset: Minutes
- Duration of acute effects: 45-90 minutes
The 0.5 mg/kg IV dose has become the benchmark in ketamine depression research. Most of the landmark clinical trials that established ketamine's rapid antidepressant effects used this dosing protocol. For a 70 kg (154 lb) patient, this translates to a 35 mg IV dose.
Intramuscular (IM) Ketamine
- Typical dose for depression: 0.5-1.0 mg/kg
- Bioavailability: Approximately 93%
- Setting: Clinical office
- Onset: 5-15 minutes
- Duration of acute effects: 60-120 minutes
IM dosing is slightly higher than IV to compensate for the small bioavailability difference and the different absorption kinetics.
Sublingual Ketamine Tablets
- Typical dose range for depression: 50-300 mg
- Common starting dose: 50-100 mg
- Bioavailability: 25-35%
- Setting: At-home with clinical supervision protocol
- Onset: 15-30 minutes
- Duration of acute effects: 60-120 minutes
The higher absolute doses for sublingual tablets reflect the lower bioavailability. A 200 mg sublingual dose with 30% bioavailability delivers approximately 60 mg of active ketamine to systemic circulation, which is comparable to IV and IM therapeutic ranges when accounting for the different pharmacokinetic profiles.
Intranasal Ketamine
- Typical dose for depression: 50-100 mg (racemic) or 56-84 mg (esketamine/Spravato)
- Bioavailability: 25-50%
- Setting: In-clinic (required for Spravato)
- Onset: 10-20 minutes
Weight-Based vs Fixed Dosing for Tablets
In IV ketamine therapy, weight-based dosing (mg/kg) is standard. For sublingual ketamine tablets, the approach varies among clinicians.
Weight-Based Starting Point
Some clinicians calculate an initial sublingual dose using body weight. A common starting formula is 0.5-1.0 mg/kg for the initial sublingual dose, with the understanding that this is conservative and will likely need upward titration.
For example:
- 60 kg patient: Starting dose of 30-60 mg sublingual
- 80 kg patient: Starting dose of 40-80 mg sublingual
- 100 kg patient: Starting dose of 50-100 mg sublingual
Fixed-Dose Protocols
Other clinicians use fixed starting doses (e.g., 50 mg or 100 mg for all patients) and titrate based on response. This approach recognizes that body weight is only one of many factors affecting response and that individual titration is necessary regardless of the starting dose.
Which Approach Is Better?
Neither approach has been definitively proven superior in clinical trials. Both converge on the same goal: finding the minimum effective dose for each individual patient through careful titration. The starting calculation matters less than the systematic adjustment process that follows.
The Titration Process
Titration is the gradual adjustment of dose to find the optimal therapeutic level. For ketamine tablets, this process typically follows a structured pattern.
Initial Phase (Sessions 1-3)
The first few sessions are primarily about establishing tolerability and getting initial response data. The clinician starts at a conservative dose and observes:
- How the patient tolerates the dissociative and physiological effects
- Whether any concerning side effects emerge (significant blood pressure elevation, excessive nausea, prolonged dissociation)
- Whether there are early signs of therapeutic response
Dose Adjustment Phase (Sessions 3-8)
Based on initial observations, the clinician adjusts the dose:
- If well tolerated but insufficient response: Increase by 25-50 mg increments
- If therapeutic response is achieved: Maintain the current dose
- If side effects are problematic: Reduce the dose or adjust administration technique
- If no response at higher doses: Reassess the treatment plan
Maintenance Phase
Once an effective dose is established, patients typically continue at that dose with a frequency determined by their response duration. Common maintenance schedules range from twice weekly to once monthly, depending on individual needs.
Dosing for Different Conditions
While the core pharmacology is the same, dosing approaches may differ based on the condition being treated.
Treatment-Resistant Depression (TRD)
Most published evidence supports starting in the range that achieves systemic exposure comparable to the 0.5 mg/kg IV benchmark. For sublingual tablets, this generally means working up to the 100-200 mg range for most patients, though some require higher doses.
Treatment frequency in the acute phase is typically twice weekly for 2-4 weeks, transitioning to weekly or biweekly sessions, and eventually monthly maintenance for responders.
Chronic Pain Conditions
Ketamine dosing for chronic pain may follow different protocols depending on the pain condition (neuropathic pain, complex regional pain syndrome, fibromyalgia, etc.). Some pain-focused protocols use lower doses than those used for depression, while others require higher doses.
The analgesic mechanisms of ketamine (NMDA receptor antagonism, anti-inflammatory effects, opioid receptor interactions) may activate at different dose thresholds than the antidepressant mechanisms, which is why pain-specific dosing is an area of active research.
Anxiety and PTSD
Emerging research on ketamine for anxiety disorders and PTSD suggests that dosing protocols similar to those used for depression may be effective, though the evidence base is still developing. Clinicians treating these conditions often start conservatively and titrate based on both symptom response and the quality of the therapeutic experience.
Factors That Influence Your Optimal Dose
Beyond body weight and the condition being treated, several factors can shift your ideal dose higher or lower.
Medications That May Interact
Certain medications can affect ketamine metabolism or response:
- Benzodiazepines: May blunt ketamine's antidepressant effects (some clinicians reduce or pause benzodiazepines during ketamine treatment)
- Lamotrigine: Some evidence suggests it may attenuate ketamine's effects, though findings are mixed
- CYP3A4 inhibitors: Medications like ketoconazole, clarithromycin, or grapefruit juice can slow ketamine metabolism, potentially increasing effective exposure
- CYP3A4 inducers: Medications like carbamazepine or rifampin can accelerate ketamine metabolism, potentially reducing effectiveness
Always provide your clinician with a complete medication list, including supplements and over-the-counter drugs.
Prior Ketamine Exposure
Patients with a history of ketamine use (medical or otherwise) may have developed some degree of tolerance. Clinicians should be aware of this history when setting initial doses.
Age
Older adults may be more sensitive to ketamine's effects and often require lower starting doses. Hepatic and renal function, which naturally decline with age, affect ketamine clearance.
Hepatic Function
Since the liver is the primary site of ketamine metabolism, patients with liver disease or impaired hepatic function may experience higher-than-expected blood levels from standard doses. Dose reductions and closer monitoring are typically warranted.
What to Expect at Different Dose Levels
While individual responses vary significantly, general patterns emerge across dose ranges for sublingual tablets.
Low Dose Range (25-75 mg sublingual)
- Mild relaxation or mood shift
- Minimal or no dissociative effects
- May be insufficient for antidepressant effect in many patients
- Useful for assessing initial tolerability
Moderate Dose Range (100-200 mg sublingual)
- Moderate dissociative effects (altered perception of time, mild visual changes, feeling of detachment)
- Therapeutic range for most depression protocols
- Blood pressure may increase modestly (typically 10-20 mmHg systolic)
- Effects last approximately 60-90 minutes
Higher Dose Range (200-300 mg sublingual)
- More pronounced dissociation
- Stronger perceptual changes
- Greater blood pressure and heart rate effects
- Used when moderate doses are insufficient
- Requires careful monitoring
Doses above 300 mg sublingual are uncommon in outpatient depression treatment and would warrant particularly close clinical oversight.
Safety Boundaries and Red Flags
Responsible ketamine dosing includes clear safety boundaries:
- Maximum dose limits: Your clinician should have a defined maximum dose they will not exceed without compelling reason
- Vital sign monitoring: Blood pressure and heart rate should be checked, particularly during dose increases
- Session environment: Patients should never drive or operate heavy machinery for at least 4-6 hours after a ketamine session
- Escalation concerns: If a patient requires rapidly escalating doses to achieve the same effect, the clinician should reassess whether ketamine therapy is appropriate
Communicating with Your Clinician About Dosing
Effective dosing requires honest, detailed communication between you and your treatment team. Helpful information to share includes:
- Onset timing: When you first notice effects after taking the tablet
- Peak intensity: How strong the effects feel at their maximum
- Duration: How long the acute effects last
- Mood effects: Any changes in mood during and in the days following the session
- Side effects: Nausea, dizziness, anxiety, blood pressure symptoms
- Functional impact: How you feel the next day and whether there is a sustained mood benefit
This feedback loop is how your clinician fine-tunes your dose to the optimal therapeutic level.
References
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders — American Psychiatric Association consensus on ketamine dosing and clinical use
- Dose-Related Effects of Ketamine for Treatment-Resistant Depression — Research examining dose-response relationships in ketamine depression treatment
- Oral Ketamine for Depression: A Systematic Review — Systematic review covering oral/sublingual ketamine dosing protocols and outcomes
- Pharmacokinetics of Ketamine: Routes of Administration — Pharmacokinetic data comparing ketamine bioavailability and dosing across routes
- NIH National Library of Medicine — Ketamine Drug Information — National Library of Medicine reference on ketamine pharmacology
- Mayo Clinic — Treatment-Resistant Depression — Mayo Clinic overview of treatment-resistant depression and emerging therapies
Share